In yesterday’s Wall Street session, Agilon Health Inc (NYSE:AGL) shares traded at $3.69, up 3.94% from the previous session.
AGL stock price is now 68.93% away from the 50-day moving average and -13.89% away from the 200-day moving average. The market capitalization of the company currently stands at $1.52B.
With the price target enhanced from $1.75 to $2.25, Citigroup Upgraded its rating from Sell to Neutral for Agilon Health Inc (NYSE: AGL). , while ‘Macquarie’ rates the stock as ‘Neutral’
In other news, McLoughlin Karen, Director bought 25,000 shares of the company’s stock on Dec 13 ’24. The stock was bought for $55,085 at an average price of $2.20. Upon completion of the transaction, the Director now directly owns 73,166 shares in the company, valued at $0.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 11 ’24, Director Battaglia Silvana bought 25,062 shares of the business’s stock. A total of $50,269 was incurred on buying the stock at an average price of $2.01. This leaves the insider owning 66,144 shares of the company worth $0.24 million. A total of 26.39% of the company’s stock is owned by insiders.
During the past 12 months, Agilon Health Inc has had a low of $1.50 and a high of $7.73. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 1.29, and a quick ratio of 1.29. The fifty day moving average price for AGL is $2.1664 and a two-hundred day moving average price translates $4.2905 for the stock.
The latest earnings results from Agilon Health Inc (NYSE: AGL) was released for 2024-09-30. The net profit margin was -6.01% and return on equity was -42.98% for AGL. The company reported revenue of $1.45 billion for the quarter, compared to $1.14 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.63 percent. For the current quarter, analysts expect AGL to generate $1.52B in revenue.
